Bright Green (OTC:BGXX) Stock, Quote.Headers.trade-ideas

Bright Green

Bright Green Corp is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured for research and pharmaceutical applications, as well as being an active ingredient in consumer-based solutions. The company plans to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).

cannabis, marijuana, weed, pot, bland, hemp, CBD, THC

Cannabis

News

Psychedelics

BGXX

Bright Green To Supply DEA-Approved Cannabis Extracts And Psychedelics To FDA-Registered Pharmaceutical Company

Penang,,Malaysia,-,Feb,2,,2021:,Gamestop,Corp,Sign,Is

Intraday Update

Markets

Movers

Trading Ideas

AMSWA

AONC

ASNS

ASXC

BBCP

BMEA

BNED

BRZE

CDXC

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CLEU

DOCU

FFIE

GERN

GRRR

LFLY

MAIA

MCRB

MITQ

MLGO

NVAX

PRST

SCNI

SIFY

SMTC

SPWR

TPHS

UPST

VERO

VLCN

YEXT

Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

movers image

Pre-Market Outlook

ESGL

SBEV

SPGC

VRAX

XYLO

Why Braze Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket

BRIGHT GREEN CORP by Bright Green Corporation

Bright Green Corp

Apollo's ATLAS SP And BNP Paribas Announce $5B Strategic Collaboration

<p>Annaly Capital Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.12, with a high estimate of $23.50 and a low estimate of $21.00. This current average reflects an increase of 7.9% from the previous average price target of $20.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726837252_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Annaly Capital Management. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.50</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jason Weaver</td>
<td>Jones Trading</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Annaly Capital Management. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Annaly Capital Management compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Annaly Capital Management's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Annaly Capital Management's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NLY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Annaly Capital Management analyst ratings.</strong></a></p>
<h2>All You Need to Know About Annaly Capital Management</h2>
<p>Annaly Capital Management Inc is an American mortgage real estate investment trust. The Company owns a portfolio of real estate related investments, including mortgage pass-through certificates, collateralized mortgage obligations, credit risk transfer securities, other securities representing interests in or obligations backed by pools of mortgage loans, residential mortgage loans and mortgage servicing rights. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The Company's three investment groups are comprised of the following: Annaly Agency Group, Annaly Residential Credit Group, Annaly Mortgage Servicing Rights Group.</p>
<h3>Key Indicators: Annaly Capital Management's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Annaly Capital Management's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-78.02%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Annaly Capital Management's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-97.19%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-0.48%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Annaly Capital Management's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.05%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Annaly Capital Management's debt-to-equity ratio is below the industry average. With a ratio of <b>1.82</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Critical Insights From Annaly Capital Management Analyst Ratings: What You Need To Know

<p>The U.S. dollar plunged to a 17-month low against the Chinese yuan after the Federal Reserve slashed rates as the People&#8217;s Bank of China held them steady overnight, raising pressures on interest-rate divergences between the <a href="https://www.benzinga.com/topic/china">world&#8217;s two major economies. </a></p>
<p>The People Bank of China (PBoC) opted to hold the one-year loan prime rate (LPR)—a critical benchmark for most corporate and household loans—at 3.35% during its September fixing. The five-year LPR, a reference for property mortgages, also remained steady at 3.85%.</p>
<p>According to the latest monetary report, China's economy grew by 5% year over year in the first half of 2024, showing resilience despite a complex global environment.</p>
<p>Inflation remained subdued, with the consumer price index (CPI) increasing by just 0.1% year-over-year. The central bank noted that while economic performance was stable, domestic issues such as &#8220;insufficient effective demand&#8221; and &#8220;the transition to new growth drivers&#8221; continue to challenge the economy.</p>
<p>The PBoC&#8217;s accommodative monetary stance is designed to provide necessary financial support for a sustainable economic recovery. However, it highlighted that external conditions remain &#8220;complex, grim, and uncertain,&#8221; contributing to a cautious approach to navigating headwinds.</p>
<h3 class="wp-block-heading">Chinese Stock Market Performance</h3>
<p>Chinese domestic stocks, as tracked by the <strong>Shanghai Composite Total Return Index</strong>, closed flat for the day, reflecting market uncertainty. However, offshore Chinese stocks fared better, with Hong Kong-listed entities, tracked via the <strong>iShares MSCI Hong Kong Index Fund </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWH#NYSE">EWH</a>), advancing by more than 1%.</p>
<p>In U.S. premarket trading, major Chinese stocks listed on American exchanges also saw gains:</p>
<ul>
<li><strong>XPeng Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>): +3.3%</li>
<li><strong>Li Auto Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>): +1.5%</li>
<li><strong>Alibaba Group Holdings Ltd.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>): +1.3%</li>
<li><strong>Tencent Music Entertainment Group </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>): +0.8%</li>
</ul>
<h3 class="wp-block-heading">Bank of Japan Holds Rates; Yen Slips</h3>
<p>In Eastern Asia, the Bank of Japan (BoJ) also held interest rates steady at 0.25%, aligning with market expectations. </p>
<p>Japan's economy showed a moderate recovery, though signs of weakness were observed in certain sectors, according to the BoJ statement.</p>
<p>On the inflation front, Japan's core CPI (excluding fresh food) has risen by 2.5-3.0% year-over-year, driven by wage increases and moderate price hikes in services.</p>
<p>Following this announcement, the Japanese yen, tracked by the <strong>Invesco CurrencyShares Japanese Yen Trust </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXY#NYSE">FXY</a>), fell by over 1% against the U.S. dollar. Meanwhile, Japanese equities rallied, with the Nikkei 225 index, as represented by the <strong>iShares MSCI Japan Index Fund </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWJ#NYSE">EWJ</a>), surging by 1.5% after a 3% gain in the earlier session.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40948624/traders-brace-for-friday-volatility-as-over-5-trillion-in-options-expire-could-trip">Traders Brace For Friday Volatility As Over $5 Trillion In Options Expire: Could &#8216;Triple Witching&#8217; Spoil Fed&#8217;s Rally?</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Asia

Currency ETFs

Global

Federal Reserve

Tech

ETFs

BABA

XPEV

Interest Rate Divergence Weakens Dollar To 17-Month Low Against Yuan: XPeng, Li Auto Among 4 Stock Movers

<p>Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $39.0, a high estimate of $56.00, and a low estimate of $30.00. Marking an increase of 25.81%, the current average surpasses the previous average price target of $31.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726837243_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Trupanion among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Greg Gibas</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Greg Gibas</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trupanion. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Trupanion compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Trupanion's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Trupanion's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TRUP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Trupanion analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Trupanion</h2>
<p>Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.</p>
<h3>Trupanion's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Trupanion's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>16.35%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Trupanion's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-1.86%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-1.92%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Trupanion's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.74%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Trupanion's debt-to-equity ratio is below the industry average at <strong>0.42</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TRUP

Unveiling 6 Analyst Insights On Trupanion

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.</p>
<h3 class="wp-block-heading"><strong>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</strong></h3>
<p><strong>Dividend Yield:</strong> 5.66%</p>
<ul>
<li><strong>Cantor Fitzgerald </strong>analyst Louise Chen reiterated an Overweight rating with a price target of $45 on Sept. 16. This analyst has an accuracy rate of 70%.</li>
<li><strong>Wells Fargo </strong>analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 78%.</li>
<li><strong>Recent News:</strong> Pfizer recently presented positive data from Phase 2 study of Ponsegromab in Patients with cancer cachexia.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://pro.benzinga.com/dashboard"> latest PFE news</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="906" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052536/image-161.png" alt="" class="wp-image-557905" style="width:703px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052536/image-161.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052536/image-161-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052536/image-161-768x708.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 4.55%</li>
<li><strong>RBC Capital </strong>analyst Ben Hendrix reiterated an Outperform rating with a price target of $68 on Sept. 4. This analyst has an accuracy rate of 74%</li>
<li><strong>Barclays </strong>analyst Andrew Mok maintained an Equal-Weight rating and cut the price target from $65 to $63 on Aug. 8. This analyst has an accuracy rate of 79%.</li>
<li><strong>Recent News:</strong> Wednesday, Oak Street Health, a subsidiary of CVS Health, agreed to settle for $60 million following allegations that it violated the False Claims Act.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://pro.benzinga.com/dashboard">trend in CVS stock</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="908" height="855" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052607/image-162.png" alt="" class="wp-image-557908" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052607/image-162.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052607/image-162-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052607/image-162-768x723.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Gilead Sciences, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</h3>
<ul>
<li><strong>Dividend Yield:</strong> 3.67%</li>
<li><strong>RBC Capital </strong>analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $72 to $74 on Sept. 4. This analyst has an accuracy rate of 65%.</li>
<li><strong>Needham </strong>analyst Joseph Stringer reiterated a Hold rating on Aug. 15. This analyst has an accuracy rate of 80%.</li>
<li><strong>Recent News:</strong> Gilead Sciences, last week, revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in GILD shares</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="891" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052656/image-163.png" alt="" class="wp-image-557910" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052656/image-163.png 891w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052656/image-163-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052656/image-163-768x725.png 768w" sizes="(max-width: 891px) 100vw, 891px" /></a></figure></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/09/40952252/nvidia-tesla-rally-as-dow-s-p-500-surge-to-fresh-highs-after-fed-cuts-rates-fear-index-remains-in-g">Nvidia, Tesla Rally As Dow, S&amp;P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In &#8216;Greed&#8217; Zone</a></strong></li>
</ul>


Dividends

Price Target

GILD

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

<p>Analysts' ratings for Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Cisco Systems and provided 12-month price targets. The average target is $55.0, accompanied by a high estimate of $60.00 and a low estimate of $49.00. Witnessing a positive shift, the current average has risen by 4.9% from the previous average price target of $52.43.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726837230_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Cisco Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Stephen Bersey</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Pierre Ferragu</td>
<td>New Street Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>George Notter</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Matthew Niknam</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$53.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$49.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Neutral</td>
<td>$58.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cisco Systems. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cisco Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Cisco Systems's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Cisco Systems's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CSCO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cisco Systems analyst ratings.</strong></a></p>
<h2>All You Need to Know About Cisco Systems</h2>
<p>Cisco Systems is the largest provider of networking equipment in the world and one of the largest software companies in the world. Its largest businesses are selling networking hardware and software (where it has leading market shares) and cybersecurity software such as firewalls. It also has collaboration products, like its Webex suite, and observability tools. It primarily outsources its manufacturing to third parties and has a large sales and marketing staff—25,000 strong across 90 countries. Overall, Cisco employs 80,000 people and sells its products globally.</p>
<h3>Cisco Systems: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Challenges:</strong> Cisco Systems's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately <strong>-10.27%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Cisco Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>15.85%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.74%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Cisco Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.75%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.68</strong>, Cisco Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CSCO

Cracking The Code: Understanding Analyst Reviews For Cisco Systems

<p>Across the recent three months, 22 analysts have shared their insights on Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Confluent, presenting an average target of $29.95, a high estimate of $38.00, and a low estimate of $23.00. Experiencing a 13.81% decline, the current average is now lower than the previous average price target of $34.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726837219_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of Confluent by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chirag Ved</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Announces</td>
<td>Neutral</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$26.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Howard Ma</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Confluent. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Confluent compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Confluent's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CFLT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Confluent analyst ratings.</strong></a></p>
<h2>Discovering Confluent: A Closer Look</h2>
<p>Confluent Inc is a new category of data infrastructure designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. Its products include Confluent Platform; Connectors; ksqlDB and others. The company generates revenue from the sale of subscriptions and services. Geographically, it derives a majority of its revenue from the United States. The company provides solutions to Financial Services; Insurance; Retail and eCommerce; Automotive; Government and other sectors.</p>
<h3>Breaking Down Confluent's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Confluent's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>24.14%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Confluent's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-38.26%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-10.46%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Confluent's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-3.62%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.27</strong>, Confluent faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CFLT

Breaking Down Confluent: 22 Analysts Share Their Views

WHLRL

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

<p>Evercore ISI Group  analyst Michael Binetti   maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Outperform and raises the price target from $105 to $110.</p>


Evercore ISI Group Maintains Outperform on Nike, Raises Price Target to $110

<p>The U.S. and Taiwan are initiating collaboration between their drone companies to create supply chains independent of China. Executives from 26 U.S. drone and anti-drone companies will arrive in Taipei on Sunday for three days of meetings with Taiwanese counterparts, military officials, and researchers.</p>
<p><strong>What Happened:</strong> The delegation includes officials from the U.S. Commerce Department, the Pentagon's Defense Innovation Unit, and Dev Shenoy, head of the Defense Department's microelectronics research and engineering. The visit underscores efforts to &#8220;de-risk&#8221; supply chains amid U.S.-China competition and security concerns over Chinese products with dual civilian and military uses, Financial Times <a href="https://www.ft.com/content/ce851c48-6aa5-48d2-b28a-6c806cc10518">reported</a> on Friday</p>
<p>The mission aims to help US companies find non-Chinese component suppliers or manufacturing partners. Taiwan's Defence Minister, <strong>Wellington Koo</strong>, stated that the visit is an opportunity for Taiwan to integrate into U.S. supply chains and engage in co-production. This integration could help Taiwan overcome export challenges due to its international status and pressure from China.</p>
<p>Among the visiting companies are <strong>AeroVironment</strong> , <strong>Dedrone</strong>, and <strong>Northrop Grumman</strong> . Taiwan's government is also boosting its drone industry, awarding NT$6.8bn ($210mn) in defence ministry orders to private companies for autonomous platforms, including microdrones and ship-borne reconnaissance drones.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/news/24/09/40890590/chuck-schumer-says-if-government-shutdown-happens-it-will-because-of-republican-poison-pills-the-ame?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chuck Schumer Says If Government Shutdown Happens It Will Be Because Of &#8216;Republican Poison Pills&#8217; — &#8216;The  American People Are Going To Hold Them Responsible&#8217;</a></strong></p>
<p><strong>Why It Matters</strong>: The collaboration between the US and Taiwan in the drone industry comes amid rising tensions with China. Recently, the US Air Force has been testing AI-powered drones, such as the <a href="https://www.benzinga.com/government/23/08/34096150/us-air-force-testing-ai-powered-enemy-fighting-drones-as-china-taiwan-tensions-simmer">XQ-58A Valkyrie</a>, which can significantly alter military warfare by evaluating enemy threats and carrying missiles.</p>
<p>Additionally, the US has approved a <a href="https://www.benzinga.com/news/24/09/40892360/us-approves-228m-military-sale-to-taiwan-to-boost-aircraft-combat-readiness-amid-rising-tensions-wit">$228 million military sale</a> to Taiwan to enhance its aircraft combat readiness. This move is part of a broader strategy to support Taiwan&#8217;s defense capabilities.</p>
<p>Moreover, the US has decided to keep a mid-range missile system in the Philippines, despite China&#8217;s demands for its removal. This <a href="https://www.benzinga.com/news/24/09/40952025/us-keeps-missiles-vital-for-defence-of-taiwan-in-philippines-despite-beijings-demands-for-removal-re">Typhon missile system</a> is seen as crucial for defending Taiwan in the event of a Chinese attack.</p>
<p>China has issued stern warnings to the US regarding interference in its sovereignty. Chinese Ambassador Xie Feng emphasized that the <a href="https://www.benzinga.com/news/24/09/40851594/chinese-ambassador-issues-stern-warning-to-us-on-red-lines-taiwan-question-is-the-most-paramount-and">Taiwan question</a> is a critical &#8220;red line&#8221; in US-China relations.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/09/40897703/former-tesla-exec-says-elon-musks-endorsement-of-trump-might-not-sway-upcoming-presidential-election?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Former Tesla Exec Says Elon Musk&#8217;s Endorsement Of Trump Might Not Sway Upcoming Presidential Elections: &#8216;Last Time Around He Endorsed Andrew Yang&#8217;</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em></p>
<p>This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <u><a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a></u></p>


Politics

General

Amid China Threat, US And Taiwan Team Up To Boost Drone Industry Cooperation To 'De-Risk' Supply Chains

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5804bb14846faa000106aa5f/dara-mohsenian">Morgan Stanley analyst Dara Mohsenian</a> downgraded the rating for <strong>PepsiCo, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and maintained the price target of $185. PepsiCo shares fell 0.3% to close at $174.66 on Thursday. <a href="https://www.benzinga.com/quote/PEP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein analyst Danilo Gargiulo downgraded <strong>Darden Restaurants, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) from Outperform to Market Perform and lowered the price target from $190 to $180. Darden shares gained 8.3% to close at $172.27 on Thursday. <a href="https://www.benzinga.com/quote/DRI/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e58f002ece4e6000120bf6b/silvan-tuerkcan">JMP Securities analyst Silvan Tuerkcan</a> downgraded <strong>Notable Labs, Ltd.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTBL#NASDAQ">NTBL</a>) from Market Outperform to Market Perform. Notable Labs shares gained 5.5% to close at $0.4780 on Thursday. <a href="https://www.benzinga.com/quote/NTBL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Matthew Hedberg downgraded the rating for <strong>Rapid7, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Outperform to Sector Perform and lowered the price target from $50 to $40. Rapid7 shares gained 1.5% to close at $34.35 on Thursday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5880b6f277f9dd00011b0aab/ravi-shanker">Morgan Stanley analyst Ravi Shanker downgraded <strong>FedEx Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from Equal-Weight to Underweight and slashed the price target from $21</a>5 to $200. FedEx shares rose 0.7% to close at $300.39 on Thursday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p><strong>Considering buying PEP stock? Here&#8217;s what analysts think</strong>: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="526" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085657/image-166-1024x526.png" alt="" class="wp-image-558335" style="width:668px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085657/image-166-1024x526.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085657/image-166-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085657/image-166-768x395.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085657/image-166.png 1306w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/09/40952252/nvidia-tesla-rally-as-dow-s-p-500-surge-to-fresh-highs-after-fed-cuts-rates-fear-index-remains-in-g">Nvidia, Tesla Rally As Dow, S&amp;P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In &#8216;Greed&#8217; Zone</a></strong></li>
</ul>


Downgrades

NTBL

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

<p>In the latest trading session, <strong>Take-Two Interactive</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttwo#NASDAQ">TTWO</a>) closed at $153.65, marking a +0.21% move from the previous day. This change lagged the S&amp;P 500&#39;s 1.7% gain on the day. Elsewhere, the Dow gained 1.26%, while the tech-heavy Nasdaq added 2.51%.</p>
<p>Shares of the publisher of &quot;Grand Theft Auto&quot; and other video games witnessed a loss of 4.21% over the previous month, trailing the performance of the Consumer Discretionary sector with its gain of 2.85% and the S&amp;P 500&#39;s gain of 1.27%.</p>
<p>Analysts and investors alike will be keeping a close eye on the performance of Take-Two Interactive in its upcoming earnings disclosure. The company is expected to report EPS of $0.42, down 65.85% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.45 billion, up 0.34% from the prior-year quarter.</p>
<p>In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.53 per share and a revenue of $5.61 billion, indicating changes of +0.8% and +5.28%, respectively, from the former year.</p>
<p>Any recent changes to analyst estimates for Take-Two Interactive should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts&#39; confidence in the company&#39;s business performance and profit potential.</p>
<p>Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we&#39;ve established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.</p>
<p>The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 6.76% higher. Right now, Take-Two Interactive possesses a Zacks Rank of #3 (Hold).</p>
<p>Digging into valuation, Take-Two Interactive currently has a Forward P/E ratio of 60.68. For comparison, its industry has an average Forward P/E of 15.85, which means Take-Two Interactive is trading at a premium to the group.</p>
<p>One should further note that TTWO currently holds a PEG ratio of 1.87. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company&#39;s expected earnings growth rate into account. The Toys - Games - Hobbies industry currently had an average PEG ratio of 1.27 as of yesterday&#39;s close.</p>
<p>The Toys - Games - Hobbies industry is part of the Consumer Discretionary sector. Currently, this industry holds a Zacks Industry Rank of 209, positioning it in the bottom 18% of all 250+ industries.</p>
<p>The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.</p>
<p><a href="https://www.zacks.com/stock/news/2338814/here-s-why-take-two-interactive-ttwo-gained-but-lagged-the-market-today?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_6v1-2338814">To read this article on Zacks.com click here.</a></p>


Earnings

Gaming

Large Cap

TTWO

Here's Why Take-Two Interactive Gained But Lagged the Market Today

<p><a href="https://www.jcapitalresearch.com/uploads/2/0/0/3/20032477/2024_09_20_inod.pdf" title="https://www.jcapitalresearch.com/uploads/2/0/0/3/20032477/2024_09_20_inod.pdf">https://www.jcapitalresearch.com/uploads/2/0/0/3/20032477/2024_09_20_inod.pdf</a></p>


Short Sellers

Short Ideas

INOD

Watching Innodata; JCapital Research Issues Report On Co Titled "More than a promote: 'Mag 7' agreements likely smaller than claimed, revenue and costs both look highly exaggerated"

<p>Wells Fargo  analyst Donald Fandetti   downgrades Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) from Overweight to Underweight and announces $20 price target.</p>


Wells Fargo Downgrades Velocity Financial to Underweight, Announces $20 Price Target

<p>Evercore ISI Group  analyst Amit Daryanani   maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Outperform and raises the price target from $55 to $60.</p>


Evercore ISI Group Maintains Outperform on Cisco Systems, Raises Price Target to $60

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

Israeli Air Strike Hits Southern Suburbs Of Lebanese Capital

<p>Wells Fargo  analyst Donald Fandetti   downgrades Ares Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRE#NYSE">ACRE</a>) from Equal-Weight to Underweight and lowers the price target from $7.5 to $7.</p>


ACRE

Wells Fargo Downgrades Ares Comml Real Est to Underweight, Lowers Price Target to $7

<p>RBC Capital  analyst Ken Herbert   maintains MDA Space (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MDA#TSX">MDA</a>) with a Outperform and raises the price target from C$18 to C$20.</p>


TSX:MDA

RBC Capital Maintains Outperform on MDA Space, Raises Price Target to C$20

<p>Evercore ISI Group  analyst Chirag Ved   maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Outperform and lowers the price target from $33 to $28.</p>


Evercore ISI Group Maintains Outperform on Confluent, Lowers Price Target to $28

WHLR

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Bright Green Corp. (BGXX) has released an update. Bright Green Corporation is on the clock to boost its share price above $1.00 to meet Nasdaq's li...

Bright Green Corp. Faces Nasdaq Delisting Challenge

Bright Green Corp. (BGXX) has released an update. Bright Green Corporation recently announced significant changes to its Board of Directors, includ...

Bright Green Corp. Announces Board Shakeup and Stock Grant

Bright Green Corp. (BGXX) has released an update. Bright Green Corporation has announced their successful acquisition of final approval from the Ne...

Bright Green Corp. Secures Key Drug Research Approvals

Bright Green Corp. (BGXX) just unveiled an announcement. Bright Green Corporation recently announced significant changes to its Board of Directors ...

Bright Green Corp Enhances Leadership and Governance

Bright Green to install 102-megawatt solar power generation field

Bright Green Corp. (BGXX) just unveiled an update. Bright Green Corporation has revised its CEO Gurvinder Singh's employment agreement, setting a r...

Bright Green Corp. Enhances CEO's Compensation and Incentives

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Bright Green</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bgxx-stock-quote/"><strong>BGXX</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Bright Green reported earnings per share of -3 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/bgxx-stock-earnings-bright-green-for-q4-of-2023/">BGXX Stock Earnings: Bright Green Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

BGXX Stock Earnings: Bright Green Reported Results for Q4 2023

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Bright Green</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bgxx-stock-quote/"><strong>BGXX</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Bright Green reported earnings per share of -1 cent.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/bgxx-stock-earnings-bright-green-for-q1-of-2024/">BGXX Stock Earnings: Bright Green Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

BGXX Stock Earnings: Bright Green Reported Results for Q1 2024

Bright Green obtained $3.5M funding commitment

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Bright Green</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bgxx-stock-quote/"><strong>BGXX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Bright Green reported earnings per share of -1 cent.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/bgxx-stock-earnings-bright-green-for-q2-of-2024/">BGXX Stock Earnings: Bright Green Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

BGXX Stock Earnings: Bright Green Reported Results for Q2 2024

Press Releases

BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS

BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR "DRUGS MADE IN AMERICA" PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS

Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.

BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING

BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.

CEO UPDATE

BRIGHT GREEN ANNOUNCES IT HAS OBTAINED A $3.5 MILLION FUNDING COMMITMENT UNDER AN EXISTING LINE OF CREDIT AND HAS ENGAGED AN INVESTMENT BANK TO SEEK A $15.0 MILLION DEBT FINANCING TO MOVE FORWARD WITH COMMERCIALIZATION.

BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.

BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.

Bright Green Corporation Provides an Update, Reinforces Commitment to Shareholders, and Focuses on Growth and Strategic Partnerships

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Bright Green

Bright Green (BGXX) Forecast

Bright Green (OTC:BGXX) Stock, Quote.Headers.trade-ideas